Investor Insights

This summary was created by AI, based on 2 opinions in the last 12 months.

Coloplast A/S (CLPBY-OTC) is navigating a challenging landscape marked by a slowdown in elective surgeries, particularly due to lingering effects from the Covid pandemic and a broader economic slowdown in China. Despite these current challenges, experts emphasize the promising long-term demand for the company's products as healthcare is expected to rebound in the upcoming years. The last decade has seen consistent dividend growth of around 11% annually, alongside a share price increase of approximately 12% annually, highlighting the company's reliability. Analysts note the strong return on invested capital and indicate that the company is poised for double-digit growth, supported by both organic growth and potential acquisitions. Overall, sentiment is positive, as many view the stock as an attractive buy with significant growth potential ahead.

Consensus
Bullish
Valuation
Undervalued
PAST TOP PICK
(A Top Pick Feb 12/24, Down 4%)

A challenging year, partly due to slowdown in China. Many products are used after elective surgeries; overhang from Covid has slowed those surgeries. Long-term, the demand is there. Past 10 years, dividend's grown ~11% a year and shares have risen by ~12% a year. 

Healthcare will see a big turnaround over the next 1-3 years. He's buying now for clients.

BUY

Everyone is on the AI-hype train. But you still have the long-term demographic of aging populations. Likes the ROIC at 14% compared to WACC at 7%. Has cashflow to make tuck-in acquisitions. You get organic revenue growth plus revenue growth from the acquisitions, and this will grow the business over time and compound. The 8th wonder of the world is time plus compounding.

Medical device industry has been slow since Covid, as everything shut down and surgeries cancelled. With rising rates, customers de-stocked inventory rather than buying more. Demand starting to pick up, so they can raise prices. Exceptionally cheap for a company that can grow 15% a year.

TOP PICK
Price target: 870.17 Danish krowns

Prices fell hard in 2022, but has partially come back as underlying growth has been robust at 8-9% organic growth in revenue per year. It pays a 2.3% dividend and offers high growth. Are the leaders in their space.

TOP PICK

It is a Danish company which is a global leader in ostomy care and continence care, and third largest in wound care. It has done two big acquisitions. It has had some weakness in 2023 but should grow through good M&A and good R&D. It has had an 11% dividend growth rate per year and 12% share growth rate per year.       Buy 9  Hold 15  Sell 3

(Analysts’ price target is $841.23)
TOP PICK
Makes catheters and colostomy bags. Elective surgeries are coming back. During pandemic, these were paused and medical device companies suffered. Their balance sheet is pristine. Number one in their business. Generate ROC close to 38%. Cost of capital is 6%. Room for R&D to move forward.
BUY ON WEAKNESS
Targeting the aging demographic. Challenge has always been its expensive valuation. If it ever goes on sale, he'd probably buy it. You never go bankrupt taking a profit. A great company.
PAST TOP PICK
(A Top Pick Jan 13/20, Up 21%) A Danish company specializing in incontinence and other medical products. A good defensive holding. They are expecting to cut revenues by 4-6%, but their margins are remaining strong as they commit to cut costs.
TOP PICK
A Danish healthcare company that focuses on wound care, skin care, digestion and other areas. Smart managers continue to focus on R&D--he likes that. Since 2015, they've increased clinical studies by 2.5x and patents by 10x. They've spent free cash flow very well. Revenues have grown 9% annually even during the Great Recession. (Analysts’ price target is $10.74)
PAST TOP PICK

(A Top Pick August 21/17, Up 24%) Colostomy bags and catheters, playing the aging demographic. Gained market share in US. Free cash flow is above competitors. Dividend grows about 10-15% per year. Investors go here to hide, so it goes up when markets go down. Buy on a pullback.

TOP PICK

Colostomy bags. The demographics are such that gastrointestinal disorders are among the bigger problems dealing with the retirees of the world. If you get a company this size growing this fast without acquisitions you have a good company. They have a history of dividend increases. (Analysts’ target: DKK 553.00).

Showing 1 to 10 of 10 entries
  • «
  • 1
  • »

Coloplast A/S(CLPBY-OTC) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 6

Stockchase rating for Coloplast A/S is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Coloplast A/S(CLPBY-OTC) Frequently Asked Questions

What is Coloplast A/S stock symbol?

Coloplast A/S is a American stock, trading under the symbol CLPBY-OTC on the US OTC (CLPBY). It is usually referred to as OTC:CLPBY or CLPBY-OTC

Is Coloplast A/S a buy or a sell?

In the last year, 6 stock analysts published opinions about CLPBY-OTC. 2 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Coloplast A/S.

Is Coloplast A/S a good investment or a top pick?

Coloplast A/S was recommended as a Top Pick by on . Read the latest stock experts ratings for Coloplast A/S.

Why is Coloplast A/S stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Coloplast A/S worth watching?

6 stock analysts on Stockchase covered Coloplast A/S In the last year. It is a trending stock that is worth watching.

What is Coloplast A/S stock price?

On 2025-03-13, Coloplast A/S (CLPBY-OTC) stock closed at a price of $10.46.